Remove 2024 Remove Ablation Remove Arrhythmia
article thumbnail

Pulsed field ablation for atrial fibrillation: a comprehensive bibliometric analysis of research trends and emerging Frontiers

Frontiers in Cardiovascular Medicine

BackgroundAtrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, posing significant health burdens. Pulsed field ablation (PFA) is an emerging non-thermal technique that is gaining traction due to the ability to selectively target myocardial cells and minimize damage to surrounding tissues.

article thumbnail

Shorten the Blanking Period After Atrial Fibrillation Ablation, Experts Say

DAIC

Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.

article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

PFA on Display As you walked into the expo hall, it was hard to miss the large space-age light displays of the Farapulse Pulsed Field Ablation system from Boston Scientific and the PulseSelect PFA system from Medtronic. Pulsed field ablation (PFA) is all the rage in electrophysiology. So, again, innovation is great.

article thumbnail

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

DAIC

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.

article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. The company received approval for this workflow from the U.S.

Ablation 105
article thumbnail

Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

DAIC

milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

article thumbnail

Preventive ablation of ventricular tachycardia avoids shocks and hospitalization, finds clinical trial

Medical Xpress - Cardiology

The late-breaking science was presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).